News | May 25, 2021
Glenmark receives ANDA approval for Icatibant Injection
This marks Glenmark's first synthetic decapeptide injectable approval
This marks Glenmark's first synthetic decapeptide injectable approval
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
A total quantum of more than 4.39 crore doses was also available for direct procurement by the states as well as private hospitals in the month of May 2021
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The agreement will help ensure wider reach and access to patients in India
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
